Adverse effects of bedaquiline in patients with extensively drug-resistant tuberculosis

BACKGROUND: The World Health Organisation (WHO) guidelines recommend that, because of the resistance patterns of extensively drug-resistant (XDR) tuberculosis (TB) and its unique mechanism of action, bedaquiline be included in the regimen. Although the results of clinical trials have shown bedaquili...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaida, Razia, Truter, Ilse, Peters, Charles A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AOSIS OpenJournals 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378113/
https://www.ncbi.nlm.nih.gov/pubmed/34485463
http://dx.doi.org/10.4102/sajid.v35i1.23

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378113/
https://www.ncbi.nlm.nih.gov/pubmed/34485463
http://dx.doi.org/10.4102/sajid.v35i1.23

Ejemplares similares